Abstract
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have